268 related articles for article (PubMed ID: 32627129)
1. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.
Cacciotti C; Choi J; Alexandrescu S; Zimmerman MA; Cooney TM; Chordas C; Clymer J; Chi S; Yeo KK
J Neurooncol; 2020 Aug; 149(1):113-122. PubMed ID: 32627129
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab in the Treatment of Recurrent or Refractory Pediatric Brain Tumors: A Single Institutional Experience.
Gorsi HS; Malicki DM; Barsan V; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
J Pediatr Hematol Oncol; 2019 May; 41(4):e235-e241. PubMed ID: 30681550
[TBL] [Abstract][Full Text] [Related]
3. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
Becher OJ; Millard NE; Modak S; Kushner BH; Haque S; Spasojevic I; Trippett TM; Gilheeney SW; Khakoo Y; Lyden DC; De Braganca KC; Kolesar JM; Huse JT; Kramer K; Cheung NV; Dunkel IJ
PLoS One; 2017; 12(6):e0178593. PubMed ID: 28582410
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
7. Reirradiation for Recurrent Pediatric Central Nervous System Malignancies: A Multi-institutional Review.
Rao AD; Rashid AS; Chen Q; Villar RC; Kobyzeva D; Nilsson K; Dieckmann K; Nechesnyuk A; Ermoian R; Alcorn S; MacDonald SM; Ladra MM; Ford EC; Winey BA; Figueiredo MLS; Chen MJ; Terezakis SA
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):634-641. PubMed ID: 29280457
[TBL] [Abstract][Full Text] [Related]
8. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.
Kline C; Liu SJ; Duriseti S; Banerjee A; Nicolaides T; Raber S; Gupta N; Haas-Kogan D; Braunstein S; Mueller S
J Neurooncol; 2018 Dec; 140(3):629-638. PubMed ID: 30206764
[TBL] [Abstract][Full Text] [Related]
9. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
[TBL] [Abstract][Full Text] [Related]
10. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
Mantica M; Pritchard A; Lieberman F; Drappatz J
J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086
[TBL] [Abstract][Full Text] [Related]
13. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
Manley PE; Trippett T; Smith AA; Macy ME; Leary SES; Boklan J; Cohen KJ; Goldman S; Kilburn LB; Dhall G; Devin J; Herzog CE; Partap S; Fauchet F; Badreddine E; Bernard JP; Chi SN
Pediatr Blood Cancer; 2018 Sep; 65(9):e27217. PubMed ID: 29750396
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.
MacDonald TJ; Vezina G; Stewart CF; Turner D; Pierson CR; Chen L; Pollack IF; Gajjar A; Kieran MW
Neuro Oncol; 2013 Oct; 15(10):1438-44. PubMed ID: 24014381
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M
Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131
[TBL] [Abstract][Full Text] [Related]
17. Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience.
Susam-Sen H; Varan A; Bajin İ; Göçmen R; Aydın B; Yalcin B; Kurucu N; Kutluk T; Bayhan T; Akyuz C
Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1769-1777. PubMed ID: 34151393
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma.
Ehlert K; Hansjuergens I; Zinke A; Otto S; Siebert N; Henze G; Lode H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414861
[TBL] [Abstract][Full Text] [Related]
19. Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.
Wei D; Zhou DJ; Datta P; Taraschenko O
Cancer Med; 2021 May; 10(9):2978-2986. PubMed ID: 33660430
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Cash T; Fox E; Liu X; Minard CG; Reid JM; Scheck AC; Weigel BJ; Wetmore C
Pediatr Blood Cancer; 2021 Sep; 68(9):e29065. PubMed ID: 33881209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
